Brief: Optomed Q4 EBITDA Loss Narrows To EUR 0.3 Mln

Optomed Oyj

17/02/2023 07:23

Feb 17 (Reuters) - Optomed Oyj  OPTOMED.HE :
    * EXPECTS ITS FULL YEAR 2023 REVENUE TO GROW COMPARED TO
2022
    * AIMS TO OBTAIN FDA CLEARANCE FOR ITS HANDHELD FUNDUS
CAMERA
AURORA TOGETHER WITH AEYE HEALTH'S AI
    * Q4 REVENUE INCREASED BY 13.0 PERCENT TO EUR 4.0 (3.6)
MILLION
    * Q4 EBITDA AMOUNTED TO EUR -0.3 (-1.5) MILLION
CORRESPONDING TO
-8.7 (-43.0) PERCENT OF REVENUE

Source text for Eikon:  ID:nWkr3wkmpW 
Further company coverage:  OPTOMED.HE 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))